- Home
- VAPE vs APLM Comparison
VAPE vs APLM Comparison
Compare VAPE & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VAPE
- APLM
- Stock Information
- Founded
- VAPE N/A
- APLM 2016
- Country
- VAPE United States
- APLM United States
- Employees
- VAPE N/A
- APLM N/A
- Industry
- VAPE
- APLM Blank Checks
- Sector
- VAPE
- APLM Finance
- Exchange
- VAPE NYSE
- APLM Nasdaq
- Market Cap
- VAPE 6.0M
- APLM 6.9M
- IPO Year
- VAPE N/A
- APLM N/A
- Fundamental
- Price
- VAPE $9.44
- APLM $6.41
- Analyst Decision
- VAPE
- APLM
- Analyst Count
- VAPE 0
- APLM 0
- Target Price
- VAPE N/A
- APLM N/A
- AVG Volume (30 Days)
- VAPE 8.4K
- APLM 4.6K
- Earning Date
- VAPE 08-13-2025
- APLM 08-13-2025
- Dividend Yield
- VAPE N/A
- APLM N/A
- EPS Growth
- VAPE N/A
- APLM N/A
- EPS
- VAPE N/A
- APLM N/A
- Revenue
- VAPE $3,282,424.00
- APLM $198,000.00
- Revenue This Year
- VAPE N/A
- APLM $415.15
- Revenue Next Year
- VAPE N/A
- APLM N/A
- P/E Ratio
- VAPE N/A
- APLM N/A
- Revenue Growth
- VAPE 33.28
- APLM N/A
- 52 Week Low
- VAPE $5.60
- APLM $4.47
- 52 Week High
- VAPE $12.26
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- VAPE N/A
- APLM 51.61
- Support Level
- VAPE N/A
- APLM $5.34
- Resistance Level
- VAPE N/A
- APLM $6.70
- Average True Range (ATR)
- VAPE 0.00
- APLM 0.52
- MACD
- VAPE 0.00
- APLM -0.03
- Stochastic Oscillator
- VAPE 0.00
- APLM 67.65
About VAPE CEA INDUSTRIES INC
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.